411 related articles for article (PubMed ID: 25346262)
1. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up.
Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2015 Apr; 62(4):577-80. PubMed ID: 25346262
[TBL] [Abstract][Full Text] [Related]
2. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns.
Garcia-Monaco R; Giachetti A; Peralta O; Napoli N; Lobos P; Gioseffi L; Mariani G
J Vasc Interv Radiol; 2012 Mar; 23(3):417-22. PubMed ID: 22365299
[TBL] [Abstract][Full Text] [Related]
3. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
6. Comment on: Steroid-resistant kaposiform hemangioendothelioma: A retrospective study of 37 patients treated with vincristine and long-term follow-up.
Adams DM; Hammill AM; Mobberley-Schuman PS; Trenor CC
Pediatr Blood Cancer; 2015 Nov; 62(11):2056. PubMed ID: 26052679
[No Abstract] [Full Text] [Related]
7. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon.
Fernandez-Pineda I; Lopez-Gutierrez JC; Chocarro G; Bernabeu-Wittel J; Ramirez-Villar GL
Pediatr Blood Cancer; 2013 Sep; 60(9):1478-81. PubMed ID: 23609996
[TBL] [Abstract][Full Text] [Related]
8. Kaposiform hemangioendothelioma: therapeutic efficacy for an enigmatic diagnosis.
Blei F
Pediatr Blood Cancer; 2015 Apr; 62(4):551-2. PubMed ID: 25559734
[No Abstract] [Full Text] [Related]
9. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
10. Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
Tlougan BE; Lee MT; Drolet BA; Frieden IJ; Adams DM; Garzon MC
J Pediatr Hematol Oncol; 2013 Nov; 35(8):618-22. PubMed ID: 23774156
[TBL] [Abstract][Full Text] [Related]
11. Vincristine and sirolimus in the treatment of kaposiform haemangioendothelioma.
Peng S; Yang K; Xu Z; Chen S; Ji Y
J Paediatr Child Health; 2019 Sep; 55(9):1119-1124. PubMed ID: 30604513
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience.
Wu HW; Wang X; Zhang L; Zhao HG; Wang YA; Su LX; Fan XD; Zheng JW
Sci Rep; 2016 Oct; 6():36261. PubMed ID: 27796340
[TBL] [Abstract][Full Text] [Related]
13. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
14. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
15. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
16. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
[No Abstract] [Full Text] [Related]
17. NEWBORNS WITH KASABACH-MERRITT PHENOMENON-ASSOCIATED KAPOSIFORM HEMANGIOENDOTHELIOMA: A REPORT OF 6 CASES.
Benzar IM; Rebenkov SO; Levytskyi AF; Fedoniuk LY; Fomina LV; Sas LM; Stravskyy TY
Wiad Lek; 2020; 73(8):1785-1789. PubMed ID: 33055352
[TBL] [Abstract][Full Text] [Related]
18. First Intracardiac Kaposiform Hemangioendothelioma in an Infant Resolved With Sirolimus: A Case Report.
Zaidi SJ; Shaik S; Agrawal C; Cossor W
J Pediatr Hematol Oncol; 2018 Oct; 40(7):536-540. PubMed ID: 30067556
[TBL] [Abstract][Full Text] [Related]
19. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Chiu YE; Drolet BA; Blei F; Carcao M; Fangusaro J; Kelly ME; Krol A; Lofgren S; Mancini AJ; Metry DW; Recht M; Silverman RA; Tom WL; Pope E
Pediatr Blood Cancer; 2012 Nov; 59(5):934-8. PubMed ID: 22648868
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety of corticosteroid and vincristine in treating kaposiform hemangioendothelioma and tufted angioma: A multicenter prospective randomized controlled clinical trial.
Yao W; Li K; Wang Z; Wang J; Ji Y; Zhou L; Huang H; Gao X; Huang Z; Gu S; Yang H; Zheng S
J Dermatol; 2021 May; 48(5):576-584. PubMed ID: 33608936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
